Email: t.p.stole@medisin.uio.no
Phone: +47 468 49 924
Education
– BSc. Biomedical Sciences, University of Westminster
– MSc. Immunology, King´s College London
Research area
- Cardiomyopathies
- Cell signaling
- Heart failure
Latest publications
Støle TP, Lunde M, Gehmlich K, Christensen G, Louch WE, Carlson CR (2024)
Exploring Syndecan-4 and MLP and Their Interaction in Primary Cardiomyocytes and H9c2 Cells
Cells, 13 (11)
PubMed 38891079 DOI 10.3390/cells13110947
Exploring Syndecan-4 and MLP and Their Interaction in Primary Cardiomyocytes and H9c2 Cells
Cells, 13 (11)
PubMed 38891079 DOI 10.3390/cells13110947
Lunde PK, Manfra O, Støle TP, Lunde M, Martinsen M, Carlson CR, Louch WE (2023)
Polyarginine Cell-Penetrating Peptides Bind and Inhibit SERCA2
Cells, 12 (19)
PubMed 37830576 DOI 10.3390/cells12192358
Polyarginine Cell-Penetrating Peptides Bind and Inhibit SERCA2
Cells, 12 (19)
PubMed 37830576 DOI 10.3390/cells12192358
Støle TP, Lunde M, Shen X, Martinsen M, Lunde PK, Li J, Lockwood F, Sjaastad I, Louch WE, Aronsen JM, Christensen G, Carlson CR (2022)
The female syndecan-4-/- heart has smaller cardiomyocytes, augmented insulin/pSer473-Akt/pSer9-GSK-3β signaling, and lowered SCOP, pThr308-Akt/Akt and GLUT4 levels
Front Cell Dev Biol, 10, 908126
PubMed 36092718 DOI 10.3389/fcell.2022.908126
The female syndecan-4-/- heart has smaller cardiomyocytes, augmented insulin/pSer473-Akt/pSer9-GSK-3β signaling, and lowered SCOP, pThr308-Akt/Akt and GLUT4 levels
Front Cell Dev Biol, 10, 908126
PubMed 36092718 DOI 10.3389/fcell.2022.908126
Wanichawan P, Skogestad J, Lunde M, Støle TP, Stensland M, Nyman TA, Sjaastad I, Sejersted OM, Aronsen JM, Carlson CR (2021)
Design of a Proteolytically Stable Sodium-Calcium Exchanger 1 Activator Peptide for In Vivo Studies
Front Pharmacol, 12, 638646
PubMed 34163352 DOI 10.3389/fphar.2021.638646
Design of a Proteolytically Stable Sodium-Calcium Exchanger 1 Activator Peptide for In Vivo Studies
Front Pharmacol, 12, 638646
PubMed 34163352 DOI 10.3389/fphar.2021.638646